

Special Issue

Porcine Bacteria and Virus Vaccines

Message from the Guest Editor

Bacteria and viruses can affect different systems in pigs, including the gastrointestinal, respiratory, reproductive, central nervous, and cardiovascular systems, resulting in various diseases in pigs. Several pathogens cause severe losses to swine production every year, including *Actinobacillus pleuropneumoniae* (APP), *Glaesserella parasuis* (GPS), African swine fever virus (ASFV), porcine epidemic diarrhea virus (PEDV), and porcine reproductive and respiratory syndrome virus (PRRSV). Studying the pathogenic mechanisms of viruses is a crucial step in disease prevention, as it facilitates the development of targeted vaccines and treatments. This Special Issue will gather the latest advances in porcine pathogens and their vaccines. Potential topics for this Special Issue include, but are not limited to, the following:

- Discovery and virulence identification of a new porcine bacterium or virus;
- Development of porcine bacterial or viral vaccines;
- Immunological assessment of porcine vaccines;
- Immune adjuvants for porcine vaccines;
- Optimization of administration route and/or formula in porcine vaccines.

Guest Editor

Dr. Huixing Lin

College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China

Deadline for manuscript submissions

25 March 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/243004

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).